137 related articles for article (PubMed ID: 24558765)
1. Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients.
Blaslov K; Zibar K; Bulum T; Duvnjak L
Acta Clin Croat; 2013 Sep; 52(3):328-36. PubMed ID: 24558765
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
3. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
[TBL] [Abstract][Full Text] [Related]
5. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
8. The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.
Kazda C; Gallwitz B; Simó R; Guzmán JR; Kraus P; Nicolay C; Rose L; Schernthaner G
Diabetes Obes Metab; 2009 Dec; 11(12):1131-7. PubMed ID: 19758357
[TBL] [Abstract][Full Text] [Related]
9. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
11. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
13. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Nelson P; Poon T; Guan X; Schnabel C; Wintle M; Fineman M
Diabetes Technol Ther; 2007 Aug; 9(4):317-26. PubMed ID: 17705687
[TBL] [Abstract][Full Text] [Related]
14. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
15. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.
Preumont V; Hermans MP; Bergman M; Buysschaert M
Acta Clin Belg; 2012; 67(6):411-5. PubMed ID: 23340146
[TBL] [Abstract][Full Text] [Related]
17. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
[TBL] [Abstract][Full Text] [Related]
18. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
[TBL] [Abstract][Full Text] [Related]
19. A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment.
Brooks AM; Lissett CA
Diabet Med; 2009 Feb; 26(2):190. PubMed ID: 19236627
[No Abstract] [Full Text] [Related]
20. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
; Probstfield JL; Hirsch I; O'Brien K; Davis B; Bergenstal R; Kingry C; Khakpour D; Pressel S; Branch KR; Riddle M
Diabetes Care; 2015 Aug; 38(8):1558-66. PubMed ID: 26068865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
